Form D · Biotechnology

AiVita Biomedical, Inc.

Irvine, CA · CIK 0001676258

Offering snapshot reported Aug 30, 2022 · SEC filing

Reported sold
$6.05M
Offering amount: $85M
Investors reported
4
Form D · investor count
Minimum accepted
$250K
Reported outside-investor minimum
First sale
Aug 24, 2022
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 30, 2022Initial$6,048,000No comparison4SEC filing
Dec 18, 2019Initial$11,000,015No comparison2SEC filing
Jul 20, 2018Initial$16,967,787No comparison8SEC filing
Mar 15, 2018Amendment$5,499,233$3,491,565vs Jun 6, 201620SEC filing
Jun 6, 2016Initial$2,007,668No comparison2SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-457482
Total amount sold includes $2,047,980 of converted indebtedness and accrued interest.

Source: Form D, filed Aug 30, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Susan Bloomfield Director
Scott Burell Executive
Chris Fibiger Director
Ed Inal Executive
Paul Jenkinson Director
Matthew Katz Director
Hans Keirstead Director, Executive
Ungbae Lee Director
Gabriel Nistor Executive
Philippe Schaison Director
Alexander Suh Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
18301 Von Karman Ave., Suite 130
Irvine, CA, 92612